Skip to content

Paige Review - FDA Promotion Rules: Questions and Answers


Answers to the questions teams ask most about Paige Review - FDA Promotion Rules. For how it works, see Paige Review - FDA Promotion Rules; for every rule it checks, see What Paige Checks.

Does it cover OPDP?

Yes. FDA’s Office of Prescription Drug Promotion (OPDP) enforces FDA’s promotion rules: 21 CFR 202.1 and FDA’s guidance on promotion. Paige Review checks your piece against those rules and against your product’s Prescribing Information. That covers:

  • risk information that is missing, played down or less prominent than the benefits
  • the boxed warning, contraindications and serious warnings
  • claims that go beyond the label, and an indication that is broadened
  • efficacy and comparisons the evidence doesn’t support
  • misleading numbers, statistics and charts
  • the established name next to the brand name

Every finding cites the regulation it relates to.

Will it tell me whether OPDP will object to a piece?

No. Paige Review isn’t an FDA or OPDP opinion, and no tool can predict one. It finds the problems FDA’s promotion rules are about before the piece reaches your review committee, so your reviewers can spend their time on judgment rather than on catching missing safety information. Your team decides on every finding.

How was it built?

The rules were written from FDA’s regulation and guidance, and chosen from the problems OPDP has cited in its untitled and warning letters. Paige is tested on pieces rebuilt from those letters, and on whether it finds the problems FDA cited. Paige applies this rulebook with a general-purpose AI model; there is no custom-trained model.

What isn’t covered yet?

  • TV, radio, video and audio, including the major statement for broadcast ads
  • The brief summary format for consumer print ads
  • Promotion of investigational products and uses
  • Vaccines and blood products, medical devices, and over-the-counter products

For anything not covered, your team’s review is the check. The What Paige Checks article lists every rule that is.

Does it replace our MLR review?

No. Paige Review is an assistant for your medical, legal and regulatory reviewers. It gives them a first pass with each finding tied to the regulation and the label, and lists what a person must still confirm. Your reviewers decide, and approval stays in your Papercurve approval workflow.

What does it check a piece against?

The piece itself (its words, layout, pictures and charts), your product’s Prescribing Information once a person on your team has verified it in Papercurve, and the studies the piece cites when they are in Papercurve as reference documents.

Does it review Spanish pieces?

Yes. Paige reviews pieces in English, in Spanish, and bilingual English and Spanish pieces. It checks Spanish against the English Prescribing Information, for example a translated indication that leaves out the adult population or the severity of the disease. Its findings are written in English and quote the Spanish words.

Does it file Form FDA 2253?

No. Paige doesn’t submit anything to FDA. Its report includes a checklist for your team, with submission on Form FDA 2253 at first dissemination.

Can it check against our own rules too?

Paige Review can be set up with a rulebook for your team’s own review standards. Contact Papercurve support to talk about it.

New in Papercurve 3: What if your content could answer back?Ask Paige turns any Papercurve library into an assistant for your team: what claims are cleared, which reference backs them, how the last piece said it. Grounded in your approved content, cited to the page.See what's new in Papercurve 3 →

Still have questions?

Email
support@papercurve.com

Chat
9am – 5pm Eastern Time, by clicking the icon in the bottom right corner of the screen.

Last updated: